On June 16, 2020, the “All of Us” Research Program, part of the National Institutes of Health, today announced that it is leveraging its significant and diverse participant base to seek new insights into COVID-19—through antibody testing, a survey on the pandemic’s impacts, and collection of electronic health record information. All of Us will make data gathered through these activities broadly accessible to approved researchers over time, in future releases of its data platform, the Researcher Workbench (https://www.researchallofus.org/), now in beta testing. Analyses may help reveal the origins of entry, spread, and impact of COVID-19 in the United States. “With our nearly 350,000 participant partners across the country, All of Us will enable the research community to answer some of today’s most critical questions and inform future preparedness efforts,” said Josh Denny, MD, All of Us’s Chief Executive Officer. All of Us will test blood samples from 10,000 or more participants who joined the program most recently, starting with samples from March 2020 and working backward until positive tests are no longer found. The tests for antibodies to the SARS-CoV-2 virus that causes COBID-19 will show the prevalence of novel coronavirus exposure among All of Us participants, and help researchers assess varying rates across regions and communities. Study collaborators include the Frederick National Laboratory for Cancer Research, supported by the National Cancer Institute; the National Institute of Allergy and Infectious Diseases; the Centers for Disease Control and Prevention; and Quest Diagnostics.
Login Or Register To Read Full Story